Crossref

2. Large-Scale Purification and Characterization of Recombinant Receptor-Binding Domain (RBD) of SARS-CoV-2 Spike Protein Expressed in Yeast

- Gaurav Nagar

- Siddharth Jain

- Meghraj Rajurkar

- Rakesh Lothe

- Harish Rao

- Sourav Majumdar

- Manish Gautam

- Sergio A. Rodriguez-Aponte

- Laura E. Crowell

- J. Christopher Love

- Prajakta Dandekar

- Amita Puranik

- Sunil Gairola

- Umesh Shaligram

- Ratnesh Jain

3. Controlling the Quality of Nanodrugs According to Their New Property—Radiothermal Emission

- Gleb V. Petrov

- Daria A. Galkina

- Alena M. Koldina

- Tatiana V. Grebennikova

- Olesya V. Eliseeva

- Yana Yu. Chernoryzh

- Varvara V. Lebedeva

- Anton V. Syroeshkin

4. Viral protein-based nanoparticles (part 2): Pharmaceutical applications

- Rocio Mellid-Carballal

- Sara Gutierrez-Gutierrez

- Carmen Rivas

- Marcos Garcia-Fuentes

5. A substitution at the cytoplasmic tail of the spike protein enhances SARS-CoV-2 infectivity and immunogenicity

- Yuhan Li

- Xianwen Zhang

- Wanbo Tai

- Xinyu Zhuang

- Huicheng Shi

- Shumin Liao

- Xinyang Yu

- Rui Mei

- Xingzhao Chen

- Yanhong Huang

- Yubin Liu

- Jianying Liu

- Yang Liu

- Yibin Zhu

- Penghua Wang

- Mingyao Tian

- Guocan Yu

- Liang Li

- Gong Cheng

6. Modularized viromimetic polymer nanoparticle vaccines (VPNVaxs) to elicit durable and effective humoral immune responses

- Zichao Huang

- Xinyu Zhuang

- Liping Liu

- Jiayu Zhao

- Sheng Ma

- Xinghui Si

- Zhenyi Zhu

- Fan Wu

- Ningyi Jin

- Mingyao Tian

- Wantong Song

- Xuesi Chen

7. Prokaryote- and Eukaryote-Based Expression Systems: Advances in Post-Pandemic Viral Antigen Production for Vaccines

- Nelli S. Khudainazarova

- Dmitriy L. Granovskiy

- Olga A. Kondakova

- Ekaterina M. Ryabchevskaya

- Angelina O. Kovalenko

- Ekaterina A. Evtushenko

- Marina V. Arkhipenko

- Nikolai A. Nikitin

- Olga V. Karpova

8. Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection

- Monrat Chulanetra

- Primana Punnakitikashem

- Kodchakorn Mahasongkram

- Wanpen Chaicumpa

- Kantaphon Glab-ampai

9. COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic

- Aleksandra Anna Zasada

- Aniela Darlińska

- Aldona Wiatrzyk

- Katarzyna Woźnica

- Kamila Formińska

- Urszula Czajka

- Małgorzata Główka

- Klaudia Lis

- Paulina Górska

10. Next-Generation Nanoparticle-Enabled mRNA Vaccines in the Treatment of COVID-19

- Eknath Kole

- Krishna Jadhav

- Raghuraj Singh

- Rahul K. Verma

- Aniruddha Chatterjee

- Jitendra Naik

11.

12. Tuning the tropism and infectivity of SARS-CoV-2 virus-like particles for mRNA delivery

- Qi Yang

- Bruce A Davidson

- Petar Pajic

- Xuyang Chen

- Omer Gokcumen

- Min Gao

- Sriram Neelamegham

13. mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions

- Ryo Okuyama

14. A Critical Assessment of COVID-19 Genomic Vaccines

- Dima A. Sabbah

- Rima Hajjo

- Suhair Sunoqrot

15. Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial

- Bei-Fang Yang

- Jing Jin

- Xi-Ran He

- Zhong-Hua Yang

- Xiao’ai Qian

- Ye-Qing Tong

- Chang-Xian Ke

- Zhao-Hong Li

- Zhao-Xia Li

- Lin-Feng Zhong

- Ze-Hong Gan

- Xian-Feng Zhang

- Ying Zeng

16. Simian Immunodeficiency Virus-Based Virus-like Particles Are an Efficient Tool to Induce Persistent Anti-SARS-CoV-2 Spike Neutralizing Antibodies and Specific T Cells in Mice

- Alessandra Gallinaro

- Chiara Falce

- Maria Franca Pirillo

- Martina Borghi

- Felicia Grasso

- Andrea Canitano

- Serena Cecchetti

- Marco Baratella

- Zuleika Michelini

- Sabrina Mariotti

- Maria Vincenza Chiantore

- Iole Farina

- Antonio Di Virgilio

- Antonella Tinari

- Gabriella Scarlatti

- Donatella Negri

- Andrea Cara

17. A perspective on SARS-CoV-2 virus-like particles vaccines

- Xiaoyang Gao

- Yeting Xia

- Xiaofang Liu

- Yinlan Xu

- Pengyang Lu

- Zhipeng dong

- Jing Liu

- Gaofeng Liang

18. An Overview of Recent Developments in the Application of Antigen Displaying Vaccine Platforms: Hints for Future SARS-CoV-2 VLP Vaccines

- Doddy Irawan Setyo Utomo

- Hamizah Suhaimi

- Nor Azila Muhammad Azami

- Fazren Azmi

- Mohd Cairul Iqbal Mohd Amin

- Jian Xu

19. VLP (Virus-Like Particles) Vaccines - Current Knowledge and Future Directions

- Prakash Meghana

- Mangalam Achuthananda Iyer Jayasri

- Krishnamurthy Suthindhiran

20. An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines

- Dona Susan Mathew

- Tirtha Pandya

- Het Pandya

- Yuzen Vaghela

- Selvakumar Subbian

21. Inducing Long Lasting B Cell and T Cell Immunity Against Multiple Variants of SARS‐CoV‐2 Through Mutant Bacteriophage Qβ—Receptor Binding Domain Conjugate

- Zibin Tan

- Canchai Yang

- Po‐han Lin

- Sherif Ramadan

- Weizhun Yang

- Zahra Rashidi

- Shuyao Lang

- Fatemeh Shafieichaharberoud

- Jia Gao

- Xingling Pan

- Nachy Soloff

- Xuanjun Wu

- Steven Bolin

- Dohun Pyeon

- Xuefei Huang

22. Platforms, advances, and technical challenges in virus-like particles-based vaccines

- Reeshu Gupta

- Kajal Arora

- Sourav Singha Roy

- Abyson Joseph

- Ruchir Rastogi

- Nupur Mehrotra Arora

- Prabuddha K. Kundu